Pelthos Therapeutics and Castle Creek Biosciences pursue merger targeting skin diseases
PTHS Pelthos Therapeutics Inc
$7.44 -7.35%
View chart & analysis → - 1Pelthos Therapeutics has agreed to merge with Castle Creek Biosciences to form a new biotech company.
- 2Castle Creek shareholders will receive 5.2 million shares of Pelthos common stock, representing 32.5% of Pelthos's fully diluted outstanding shares upon closing the deal.
- 3The transaction is expected to be completed by the end of the first quarter of 2027.
So what's the key point?
Pelthos Therapeutics and Castle Creek Biosciences have decided to join together. Castle Creek shareholders will receive 5.2 million shares of Pelthos stock once the merger is finished.
Source Pharmaceutical Technology · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.